From the New York Times:
Johnson & Johnson Reports Reminyl Deaths
By THE ASSOCIATED PRESS
Published: January 21, 2005
Filed at 5:08 p.m. ET
RARITAN, N.J. (AP) -- Patients taking Alzheimer's drug Reminyl in a test for another use had higher death rates than those taking a placebo, Johnson & Johnson Pharmaceutical Research & Development LLC announced Friday.
The patients had mild cognitive impairment, and the J&J company is no longer pursuing Reminyl as a treatment for the condition and has not submitted any applications for such use, spokeswoman Carol Goodrich said.
Reminyl was approved in 2001 as a treatment for mild to moderate Alzheimer's disease. The higher death rate was not observed in Alzheimer's trials, Goodrich said.
[ ... Read the full article ...] (free registration required)